drugs

Dr. M’s Women and Children First Podcast #107: Sundeep Dugar, PhD – Drug Discovery


On today’s episode of Dr. M’s Women and Children First Podcast, we welcome a scientist whose work has quietly shaped the cardiovascular health of millions around the world.

Dr. Sundeep Dugar is a pharmaceutical innovator, inventor, and industry leader with more than three decades at the forefront of drug discovery. He is best known as a co-inventor of ezetimibe — marketed as Zetia® — a landmark cholesterol-lowering medication that transformed lipid management by targeting intestinal cholesterol absorption. He also co-inventor of the combination therapy Vytorin® (ezetimibe plus simvastatin), expanding treatment options for patients at high cardiovascular risk. For this groundbreaking work, Dr. Dugar and his colleagues received the prestigious 2005 National Inventor of the Year Award from the Intellectual Property Owners Association and the Heroes of Chemistry award from the American Chemical Society. Across his career, Dr. Dugar has contributed to more than 140 patents and has authored over 70 scientific publications, reflecting a lifetime devoted to translating chemistry into real-world therapies.

He is currently the founder of Aayam Therapeutics, where he leads efforts to develop innovative, accessible medicines through collaborative global research. He also serves as Co-Chief Executive Officer of Blue Oak Nutraceuticals, advancing a novel mitochondrial-targeted compound known as Mitokatlyst™, designed to stimulate mitochondrial biogenesis and cellular energy — with potential implications for muscle strength, metabolic health, cardiovascular function, and inflammation. He is the first one to decipher the mechanism by which exercise induces mitochondria levels. Mitokatlyst mechanism of action mimics this process.

Dr. Dugar’s scientific journey spans continents and some of the world’s premier institutions. He earned both his Bachelor’s and Master’s degrees in Organic Chemistry from the University of Delhi, completed his PhD in Chemistry at the University of California, Davis, and pursued postdoctoral research at ETH Zürich in Switzerland and at Cornell University.
Today, we’ll explore the story behind major pharmaceutical breakthroughs, the science of mitochondrial health, and what the future of therapeutics may look like when innovation meets global accessibility.

Please join me in welcoming Dr. Sundeep Dugar.

Dr. M’s Women and Children First Podcast #106: Nayan Patel, PharmD – Glutathione


Welcome back to Dr. M’s Women and Children Firsts Podcast. Today’s conversation sits at the crossroads of chemistry, skepticism, and clinical innovation.

Our guest is Nayan Patel, a pharmacist with more than three decades inside the world of drug formulation and delivery. He is an alumnus of the University of Southern California School of Pharmacy, where he now serves as adjunct faculty, teaching advanced biochemistry and compounding science. Over the years, he has become an international educator on one molecule that refuses to stay quiet: glutathione.

Dr. Patel is the founder of Auro Wellness, launched in 2011 with a specific mission—stabilize glutathione and solve its delivery problem. His work led to the development of the Auro GSH™ Antioxidant Delivery System, a topical approach designed to improve absorption of this notoriously fragile molecule. He is also the author of The Glutathione Revolution, a deep dive into how glutathione influences detoxification, aging, energy production, and immune resilience.

If you’ve spent time in integrative medicine, you’ve heard glutathione called the “master antioxidant.” That phrase can sound like marketing, but the biology is real. Glutathione is a three–amino acid peptide central to redox balance, mitochondrial function, immune signaling, and cellular survival. It does not just neutralize oxidative stress; it regulates how cells respond to it.

The challenge is delivery. Oral glutathione is largely broken down in the gut. IV glutathione works, but it’s impractical for most families. Precursors like NAC depend on intact metabolic pathways that may not be operating optimally in states of chronic stress or inflammation.
Dr. Patel asked a disruptive question: what if the bottleneck isn’t production—but delivery?

Today we unpack the science and the skepticism around transdermal glutathione. Can a molecule like this meaningfully cross the skin barrier? What does stabilization actually require? And how does independent pharmaceutical innovation differ from traditional drug development pathways, which are often constrained by economics as much as biology?

For those of us caring for women and children—where oxidative stress, immune dysregulation, mitochondrial strain, and toxic burden intersect in everything from complicated pregnancies to neurodevelopmental challenges—this conversation matters. Not as a silver bullet. Not as a miracle spray. But as an exploration of foundational physiology and thoughtful delivery science.

This is a discussion about how molecules move, how systems adapt, and how asking better questions can reshape clinical practice.
Let’s dive in.

Dr. M

Auro Wellness

Dr. M’s Women and Children First Podcast #98 William Parker, PhD – Acetaminophen and Autism – What Do We Know in 2025?

Welcome to Dr. M’s Women & Children First Podcast, where we engage with pioneering voices at the intersection of science, healthcare, and the well-being of families.

Today, I’m honored to introduce Dr. William Parker, PhD. Dr. Parker is perhaps best known for discovering the function of the human appendix, but his contributions to science extend far beyond that single discovery. He studied biology and chemistry as an undergraduate before earning his PhD in Chemistry from the University of Nebraska–Lincoln in 1992. Since the 1980s, he has conducted innovative research, publishing more than 150 peer-reviewed articles that span immune function, microbiome science, and human health.

Dr. Parker was the first to compare immune systems in wild animals with those of their laboratory counterparts, and among the first to conclude that changes in the human “biota”, the symbiotic organisms living within us, brought on by modern society can contribute to depression and anxiety. After nearly three decades at Duke University, where he served as associate professor and research leader, he founded WPLab, Inc., a nonprofit dedicated to understanding and educating about the causes of chronic inflammatory diseases in high-income societies.

Currently a visiting scholar at the University of North Carolina, Dr. Parker collaborates widely with colleagues from Duke University, University of Montreal, Czech Academy of Sciences, University of Groningen, University of Colorado Boulder, and scientists across the pharmaceutical industry.

In recent years, he has turned his attention to a provocative and urgent question: the potential links between early acetaminophen exposure and autism spectrum outcomes. His current work combines mechanistic and epidemiologic approaches to explore how acetaminophen’s effects on human physiology at critical stages of development might influence neurodevelopment.

In our conversation, we’ll explore:

  • The evidence and hypotheses behind acetaminophen’s potential role in autism risk
  • What families and clinicians should know: what’s plausible, what remains speculative, and where research is heading next

I’m thrilled to share this episode with Dr. Parker, whose intellectual curiosity, scientific rigor, and courage to ask difficult questions embody the spirit of this show.

Dr. M

Dr. M’s SPA Newsletter Volume 15 Issue 13

Literature Review

1) An exciting phase three trial with the CETP inhibitor Obicetrapib has shown serious promise for ASCVD and Alzheimer’s Disease (AD). “In BROADWAY, a pre-specified AD sub-study was designed to assess plasma AD biomarkers in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified population of ApoE3/4 or 4/4 carriers. The sub-study included 1727 patients, including 367 ApoE4 carriers. The primary outcome measure was p-tau217 absolute and percent change over 12 months. Additional outcome measures included neurofilament light chain (“NFL”), glial fibrillary acidic protein (“GFAP”), p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215).” (NAMS)

Obicetrapib has shown significant LDL and Lp(a) lowering effects as well in early trials. I will be watching this discovery closely as it may be a game changer for these diseases. “In the BROADWAY trial, more than 2,500 participants with established heart disease or genetic high cholesterol were given either Obicetrapib or a placebo, in addition to their regular cholesterol medications. After 12 weeks, those on Obicetrapib had dropped their LDL cholesterol by 32.6 per cent and Lp(a) by 33.5 per cent on average – many achieved guideline-recommended targets for the first time.” (Sci Tech Daily) The drop in Lp(a) is the profound result as this is a massive risk factor for ASCVD and to date is not moveable by statins and most used meds.

2) GLP1 drugs and risk for macular degeneration?… and more

Dr. M

Dr. M’s Women and Children First Podcast #20 Reboot – Sandy Newmark, M.D. – ADHD Part II

ADHD without Drugs – This is a reboot of this podcast from 2022 as it aligns with the podcasts of Dr. James Greenblatt and Dr. Kate Henry
Sandy Newmark, MD is the Director of Clinical Programs at the University of California at San Francisco’s Osher Center for Integrative Health. He is an Integrative Pediatrician and a Professor in the Department of Pediatrics at UCSF with the title of Osher Foundation Endowed Chair in Clinical Programs in Integrative Medicine. To me, he is an amazing teacher and onion peeler in the world of attention deficit.
I met Sandy back in 2006 as he was the lead Pediatric teacher in the University of Arizona’s Integrative Medicine Fellowship. He immediately made an impact in my career as a leader in this new way of seeing the world of medicine.
His bio lists: Dr. Sanford Newmark specializes in integrative neurodevelopmental pediatrics including autism, ADHD, and related conditions. Dr. Newmark lectures widely on both autism and ADHD and has authored three chapters in integrative medicine textbooks. He is the author of the book “ADHD Without Drugs, a Guide to the Natural Care of Children with ADHD.” His online video, “Do 2.5 Million Children Really Need Ritalin? An Integrative Approach to ADHD,” has been viewed over 4.5 million times.
Know this, this is an hour of your life that you will want to dedicate to Dr. Newmark’s thoughts. Especially, if you or your child has ADHD.
Enjoy my conversation with Dr. Newmark,
Dr. M

Dr. M’s SPA Newsletter Audiocast Volume 13 Issue 23

Literature Review: This week we discuss articles about the Inhalation of polyamides or nylon in microsizes, masking and effectiveness, cannabis use in youth and covid 19 versus influenza and more. Part two is a look at research related to pollution and the risk of cardiac disease.

Enjoy,

Dr. M

 

Dr. M’s SPA Newsletter Audiocast Volume 13 Issue 4

This week we do a literature review looking at Neurology with specific stops at sleep loss and emotional regulation, APOE4 and Alzheimer’s Disease, memory consolidation with sleep versus wake, gaslighting and more . We also look at potassium as a mineral of necessity. We finish with obesity and Semaglutide.   Enjoy, Dr. M